UK 383367BMP-1/PCP inhibitor,potent and selective CAS# 348622-88-8 |
- Batimastat (BB-94)
Catalog No.:BCC1223
CAS No.:130370-60-4
- GM 6001
Catalog No.:BCC2119
CAS No.:142880-36-2
- Ro 32-3555
Catalog No.:BCC2377
CAS No.:190648-49-8
- PD 166793
Catalog No.:BCC2376
CAS No.:199850-67-4
- CP 471474
Catalog No.:BCC2373
CAS No.:210755-45-6
- ARP 100
Catalog No.:BCC2370
CAS No.:704888-90-4
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 348622-88-8 | SDF | Download SDF |
| PubChem ID | 9818682 | Appearance | Powder |
| Formula | C15H24N4O4 | M.Wt | 324.38 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO | ||
| Chemical Name | 5-[(3R)-6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl]-1,2,4-oxadiazole-3-carboxamide | ||
| SMILES | C1CCC(CC1)CCCC(CC(=O)NO)C2=NC(=NO2)C(=O)N | ||
| Standard InChIKey | ARJCBSRIPGJMAD-LLVKDONJSA-N | ||
| Standard InChI | InChI=1S/C15H24N4O4/c16-13(21)14-17-15(23-19-14)11(9-12(20)18-22)8-4-7-10-5-2-1-3-6-10/h10-11,22H,1-9H2,(H2,16,21)(H,18,20)/t11-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent and selective inhibitor of BMP-1 (procollagen C-proteinase; PCP) (IC50 = 44 nM). Selective for BMP-1 over MMPs 1, 2, 3, 9 and 14 (IC50 values are >10,000 nM for listed MMPs). |
UK 383367 Dilution Calculator
UK 383367 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0828 mL | 15.414 mL | 30.828 mL | 61.6561 mL | 77.0701 mL |
| 5 mM | 0.6166 mL | 3.0828 mL | 6.1656 mL | 12.3312 mL | 15.414 mL |
| 10 mM | 0.3083 mL | 1.5414 mL | 3.0828 mL | 6.1656 mL | 7.707 mL |
| 50 mM | 0.0617 mL | 0.3083 mL | 0.6166 mL | 1.2331 mL | 1.5414 mL |
| 100 mM | 0.0308 mL | 0.1541 mL | 0.3083 mL | 0.6166 mL | 0.7707 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
UK 383367 is a novel procollagen C-protein (PCP) inhibitor being investigated for the treatment of post-surgical dermal scarring, which potently inhibits the activity of PCP with the value of 50% inhibition concentration IC50 of 44 nM, as well as a selective inhibitor of matrix metalloproteinases (MMPs) with values of IC50 >60,000 nM for MMP-2 and >10,000 nM for MMP-1, MMP-3, MMP-9 and MMP-4. Although the mechanism is not clear yet, UK 383367 also exhibits weak inhibitory effects against phosphodiesterase-4 (PDE-4) enzyme, including PDE-4a, PDE-4b, PDE-4c and PDE-4d, with values of IC50 of 1.8 μM, 1.5 μM, 2.4 μM and 0.9 μM respectively.
Reference
G. A. Allan, J. I. Gedge, A. N. R. Nedderman, S. J. Roffey, H. F. Small and R. Webster. Pharmacokinetics and metabolism of UK-383,367 in rats and dogs: a rationale for long-lived plasma radioactivity. Xenobiotica 2006; 36(5): 399-418
Bailey S, Fish PV, Billotte S, Bordner J, Greiling D, James K, McElroy A, Mills JE, Reed C, Webster R.ff. Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents. Bioorg Med Chem Lett. 2008;18(24):6562-6567
- Palmatine
Catalog No.:BCN5285
CAS No.:3486-67-7
- Coptisine
Catalog No.:BCN6320
CAS No.:3486-66-6
- Optovin
Catalog No.:BCC6323
CAS No.:348575-88-2
- Methyl 3-methoxyacrylate
Catalog No.:BCN2258
CAS No.:34846-90-7
- 12-Hydroxyabietic acid
Catalog No.:BCN5284
CAS No.:3484-61-5
- Metiamide
Catalog No.:BCC1742
CAS No.:34839-70-8
- Bz-Tyr-Oet
Catalog No.:BCC3122
CAS No.:3483-82-7
- DL-Dithiothreitol
Catalog No.:BCC7586
CAS No.:3483-12-3
- 4'-Demethyleucomin
Catalog No.:BCN5283
CAS No.:34818-83-2
- Marilactone
Catalog No.:BCN7363
CAS No.:34818-17-2
- 8-Acetonyldihydroavicine
Catalog No.:BCN3303
CAS No.:348098-59-9
- BAY 57-1293
Catalog No.:BCC4050
CAS No.:348086-71-5
- Vineridine
Catalog No.:BCN5286
CAS No.:3489-06-3
- HC-030031
Catalog No.:BCC4910
CAS No.:349085-38-7
- GSK 137647
Catalog No.:BCC8045
CAS No.:349085-82-1
- JX 401
Catalog No.:BCC7443
CAS No.:349087-34-9
- Cryptomeridiol 11-rhamnoside
Catalog No.:BCN4648
CAS No.:349112-30-7
- S-Adenosyl-L-Methionine iodide salt
Catalog No.:BCN2232
CAS No.:3493-13-8
- Alda 1
Catalog No.:BCC6096
CAS No.:349438-38-6
- Methyl dodonate A acetate
Catalog No.:BCN4647
CAS No.:349487-98-5
- Methyl dodonate A
Catalog No.:BCN4646
CAS No.:349534-70-9
- Dodonolide
Catalog No.:BCN4645
CAS No.:349534-73-2
- 3'',4''-Di-O-acetyl-2'',6''-di-O-p-coumaroylastragalin
Catalog No.:BCN6843
CAS No.:349545-02-4
- Z-Val-OSu
Catalog No.:BCC2733
CAS No.:3496-11-5
Pharmacokinetics and metabolism of UK-383,367 in rats and dogs: a rationale for long-lived plasma radioactivity.[Pubmed:16854779]
Xenobiotica. 2006 May;36(5):399-418.
UK-383,367 (5-{(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl}-1,2,4-oxadiazole-3-ca rboxamide) is a novel procollagen C-proteinase inhibitor evaluated for the treatment of post-surgical dermal scarring. It is extensively metabolized in rat and dog absorption, distribution, metabolism and excretion studies, and a metabolic pathway for UK-383,367 was determined. A long-lived metabolite was identified in dog plasma. Data indicate that this metabolite results from the oxadiazole ring-cleavage-producing oxamic acid, oxamide and oxalic acid. Ion exclusion chromatography was used to identify these polar metabolites, which were unretained on a standard reversed-phase high-performance liquid chromatography system. The oxamide metabolite was identified as the long-lived radioactivity, which was observed in dog plasma.
Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.[Pubmed:18945617]
Bioorg Med Chem Lett. 2008 Dec 15;18(24):6562-7.
Succinyl hydroxamates 1 and 2 are disclosed as novel series of potent and selective inhibitors of procollagen C-proteinase (PCP) which may have potential as anti-fibrotic agents. Carboxamide 7 demonstrated good PCP inhibition and had excellent selectivity over MMPs involved in wound healing. In addition, 7 was effective in a cell-based model of collagen deposition (fibroplasia model) and was very effective at penetrating human skin in vitro. Compound 7 (UK-383,367) was selected as a candidate for evaluation in clinical studies as a topically applied, dermal anti-scarring agent.
Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.[Pubmed:17591762]
J Med Chem. 2007 Jul 26;50(15):3442-56.
6-Cyclohexyl-N-hydroxy-3-(1,2,4-oxadiazol-5-yl)hexanamides were previously disclosed as inhibitors of procollagen C-proteinase (PCP) culminating in the identification of amide 1. Our objective was to discover a second inhibitor that would have improved affinity for PCP and to optimize properties for transepidermal delivery (TED) to intact skin. Further investigation of this template identified a number of potent PCP inhibitors (IC50 values of 2-6 nM) with improved TED flux. Sulfonamide 56 had excellent PCP enzyme activity when measured with a peptide substrate (Ki 8.7 nM) or with the endogenous substrate procollagen (IC50 3.4 nM) and demonstrates excellent selectivity over MMPs involved in wound healing (>10 000-fold). In the fibroplasia model, 56 inhibited deposition of insoluble collagen by 76 +/- 2% at 10 microM and was very effective at penetrating human skin in vitro with a TED flux of 1.5 microg/cm2/h, which compares favorably with values for agents that are known to penetrate skin well in vivo. Based on this profile, 56 (UK-421,045) was selected as a candidate for further preclinical evaluation as a topically applied, dermal anti-scarring agent.
